造血干细胞重编程的探索与进展  

The Progress of Exploration in Reprograming Hematopoietic Stem Cell in Vitro

作　　者：程小岩 许艾宁 刘丹[1] 黄秋花[1] 陈赛娟[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院上海血液学研究所医学基因组学国家重点实验室,上海200025

出　　处：《中国基础科学》2017年第3期20-26,共7页China Basic Science

基　　金：国家重大科学研究计划(2013CB966800)

摘　　要：随着临床血液需求不断增长,血制品供不应求的现象愈发严重,特别是可供临床治疗性移植的造血干细胞(HSC)尤为缺乏。然而,供者来源的缺乏一直是制约其应用发展的主要瓶颈。随着体细胞重编程与转分化研究的兴起和稳步发展,体外造血干细胞的获得成为可能,为临床治疗带来新的希望。然而,体外获得临床治疗级的造血干细胞尚面临严峻挑战,虽然诱导多能干细胞体外定向分化及体细胞转分化获得的造血干细胞已获得了可喜的进步,但其尚未在体内获得造血重建。因此,对造血干细胞的研究任重而道远,加深对造血干细胞的认识,积极创新体外获得造血干细胞的途径和方法,有可能为患者提供新的治疗手段。Clinical blood demand is growing,blood products,especially hematopoietic stem cells（ HSC） for clinical treatment,are in short supply. However,the shortage of donor HSCs has always been the bottleneck in HSCT development. With the studies of somatic cell reprogramming and trans-differentiation springing up,generating HSC in vitro has come true. This offers a new opportunity for clinical therapy. Nevertheless,in vitro generation of HSCs still faces many challenges. The method of obtaining HSC-like cells from pluripotent stem cell differentiation and somatic cell trans-differentiation in vitro have progressed. There is still an impairment in long-term hematopoietic reconstitution. In order to push its clinical application forward,great efforts need to be made to generate HSCs in vitro.

关 键 词：造血干细胞 诱导多能干细胞 转分化 

分 类 号：Q23[生物学—细胞生物学]